Nearly half (51 percent) of Americans said they would definitely or probably get a COVID-19 vaccine if it were available today, while 49 percent said they definitely or probably would not, according to...
Although prices for migraine medications rose by 40 percent through 2017, they sharply declined at the beginning of 2018 and haven’t seen much of an increase since, according to a GoodRx report....
Gauss and Cellex recently announced an exclusive partnership to launch the first-ever rapid, at-home COVID-19 antigen test.
Once approved by FDA, the test would be the first to allow individuals to...
Johnson & Johnson recently announced that its lead COVID-19 vaccine candidate, Ad26.COV2.S, showed positive outcomes in preclinical studies using hamsters.
The data, published in Nature...
In critically ill COVID-19 patients, administration of systemic corticosteroids compared with standard care was associated with lower 28-day all-cause mortality, according to a recent JAMA Network Open...
Drug rebates are distorting the market for branded drugs and producing outcomes that may be harmful to both patients and the healthcare system, according to a recent study by the Pioneer Institute.
In...
FDA recently issued an emergency use authorization to Abbott for the first COVID-19 antigen test where results can be read directly from the testing card.
The BinaxNOW Ag Card is fast and...
Eli Lilly recently announced positive Phase 3 clinical trial results for its type 2 diabetes drug, Jardiance, when used by adults with heart failure with reduced ejection fraction.
The trial,...
New drugs and therapies must undergo a series of tests and studies in order to help the individuals who need a cure or treatment for their conditions. These clinical trials are key to ensuring safety...
AstraZeneca recently announced that its COVID-19 vaccine, AZD1222, expanded into a Phase 3 clinical trial in the US to assess its safety, efficacy, and immunogenicity.
The trial, D8110C00001, is...
The National Academies of Sciences, Engineering, and Medicine recently released a discussion draft of a preliminary framework to assist policymakers in planning for equitable allocation of a COVID-19...
GlaxoSmithKline (GSK) and Vir Biotechnology recently announced that the first patient was dosed in a Phase 2/3 study evaluating the safety and efficiency of a COVID-19 antibody treatment.
The...
FDA recently broadened an emergency use authorization for remdesivir to include all hospitalized adult and pediatric patients with COVID-19.
For more coronavirus updates, visit our resource page,...
From 2000 to 2019, composition and design of clinical trials changed substantially by sponsor type, suggested a need for increased funding for larger randomized trials , a JAMA Network Open study...
Mount Sinai researchers recently released additional information regarding the positive connection between anticoagulation therapy and improved survival among hospitalized COVID-19 patients.
For more...
Although remdesivir showed clinical benefit in patients with severe COVID-19, it showed little benefit on clinical status for moderately ill COVID-19 patients , a recent JAMA Network Open study...
Roche and Regeneron recently announced a partnership to develop, manufacture, and distribute Regeneron’s investigational COVID-19 antibody combination.
For more coronavirus updates, visit...
Although 61 percent of healthcare providers communicate with pharmaceutical sales representatives now more than before COVID-19, they stressed that sales reps fail to understand the real impact of the...
Patients with deductibles and coinsurance for brand medicines have significantly higher annual out-of-pocket costs than patients with fixed copays alone, according to a new analysis.
The analysis...
Knowledge Ecology International (KEI) recently filed a petition calling on the FDA to ban music in the sections of direct-to-consumer advertisements for pharmaceuticals that address side effects and...
